PD-1/PD-L1 inhibitors plus chemotherapy improve progression-free and overall survival in pMMR metastatic colorectal cancerCombination therapy shows promise for metastatic colorectal cancer patients

Frontiers in Medicine Published October 22, 2026 DOI ↗ Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider PD-1/PD-L1 inhibitors plus chemotherapy as a potential first-line option for pMMR metastatic colorectal cancer.

This meta-analysis evaluated the efficacy of PD-1/PD-L1 inhibitors combined with chemotherapy (with or without targeted agents) in 1,165 patients with proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC). The analysis indicates that this combination significantly improves progression-free survival (PFS) with an HR of 0.84 (95%CI 0.73, 0.95; P=0.007) and overall survival (OS) with an HR of 0.83 (95%CI 0.73, 0.94; P=0.004).

Several subgroups demonstrated more pronounced benefits for PFS. These included patients with KRAS mutations (HR 0.49; 95%CI 0.30, 0.80; P=0.005), liver metastases (HR 0.82; 95%CI 0.68, 0.98; P=0.027), and PD-L1 CPS < 1 (HR 0.53; 95%CI 0.30, 0.95; P=0.032). Other subgroups showing greater benefit included those with ECOG performance status of 0 (HR 0.73; P=0.018), no prior adjuvant therapy (HR 0.81; P=0.030), and synchronous metastases (HR 0.79; P=0.037).

The authors note that these subgroup findings are exploratory and interaction tests were not performed. These results suggest that PD-1/PD-L1 inhibitors combined with chemotherapy may be a viable first-line treatment option for patients with pMMR metastatic colorectal cancer.

How this fits prior evidence

This meta-analysis addresses a gap in the management of pMMR metastatic colorectal cancer by providing evidence for the use of PD-1/PD-L1 inhibitors combined with chemotherapy. While previous evidence has established the efficacy of PD-1/PD-L1 inhibitors in other solid tumors, such as cervical cancer and hepatocellular carcinoma, this study specifically quantifies the benefit in the pMMR colorectal population. It also highlights specific subgroups, such as those with KRAS mutations, that may derive greater benefit from this combination.

Living with metastatic colorectal cancer is incredibly difficult, and finding a treatment that works is a top priority for patients and their families. New data suggests that combining certain immunotherapies, known as PD-1 or PD-L1 inhibitors, with chemotherapy may offer a better path forward for those with a specific genetic profile (pMMR).

Researchers looked at data from 1,165 patients to see how this combination performed. The results showed that this treatment approach helped prolong both the time before the cancer progressed and the overall survival of the patients. The study also noted that some groups, such as men and those with specific mutations, saw even greater benefits in terms of progression-free survival.

While these results are encouraging for potential first-line treatment, it is important to note that some of the specific group findings are exploratory. Because the researchers did not perform certain interaction tests, these specific results should be viewed as preliminary evidence. Talk to your doctor to see if this combination is a right option for your specific situation.

What this means for you:

Combining PD-1 or PD-L1 inhibitors with chemotherapy may extend survival for certain colorectal cancer patients.

Common questions

What did the study find about the combination treatment?

The study of 1,165 patients showed that combining PD-1 or PD-L1 inhibitors with chemotherapy helped prolong both progression-free survival and overall survival for those with pMMR metastatic colorectal cancer. This means the treatment helped slow the cancer's growth and extended life for the patients involved.

Are there specific groups that saw more benefit?

Several groups showed greater benefits in progression-free survival, including men, patients with liver metastases, and those with KRAS mutations. However, the researchers noted that these specific subgroup findings are exploratory and were not confirmed with interaction tests.

Is this a new way to treat colorectal cancer?

This combination of immunotherapies and chemotherapy is being looked at as a potential first-line treatment option. Because the findings for specific subgroups are exploratory, you should discuss these results with your doctor to see how they apply to your specific diagnosis.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedOct 2026

View Original Abstract ↓

BackgroundThe clinical efficacy of PD-1/PD-L1 inhibitors combined with chemotherapy (± targeted agents) in patients with proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) remains unclear. This study systematically evaluated the efficacy of this regimen.MethodsWe searched PubMed, Web of Science, Embase, the Cochrane Library, and ClinicalTrials.gov for relevant randomized controlled trials (RCTs) published up to May 2026. The primary outcomes were progression-free survival (PFS) and overall survival (OS); effect sizes were estimated as hazard ratios (HRs) and 95% confidence intervals (95%CIs).ResultsSix RCTs comprising 1,165 participants were included. The addition of PD-1/PD-L1 inhibitors to chemotherapy, with or without anti-VEGF agents, was associated with prolonged PFS (HR = 0.84, 95%CI [0.73, 0.95], P = 0.007) and OS (HR = 0.83, 95%CI [0.73, 0.94], P = 0.004). Subgroup analyses for PFS preliminarily suggested greater benefit in male patients (HR = 0.77, 95%CI [0.64, 0.94], P = 0.010), those with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 (HR = 0.73, 95%CI [0.56, 0.95], P = 0.018), those with liver metastases (HR = 0.82, 95%CI [0.68, 0.98], P = 0.027), those without prior adjuvant therapy (HR = 0.81, 95%CI [0.67, 0.98], P = 0.030), those with a PD-L1 combined positive score (CPS) < 1 (HR = 0.53, 95%CI [0.30, 0.95], P = 0.032), those with synchronous metastases (HR = 0.79, 95%CI [0.63, 0.99], P = 0.037), and those with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations (HR = 0.49, 95%CI [0.30, 0.80], P=0.005). These subgroup findings are exploratory, and interaction tests were not performed.ConclusionsPD-1/PD-L1 inhibitors combined with chemotherapy (with or without targeted agents) may improve the prognosis of patients with pMMR mCRC and represent a potential first-line treatment option.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261330186.

PD-1/PD-L1 inhibitors plus chemotherapy improve progression-free and overall survival in pMMR metastatic colorectal cancerCombination therapy shows promise for metastatic colorectal cancer patients

How this fits prior evidence

Common questions

Study Details

First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer

Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival

Clinical research that matters. Delivered to your inbox.

PD-1/PD-L1 inhibitors plus chemotherapy improve progression-free and overall survival in pMMR metastatic colorectal cancerCombination therapy shows promise for metastatic colorectal cancer patients

How this fits prior evidence

Common questions

More on Colorectal Cancer

Study Details

First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer

Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival

Clinical research that matters. Delivered to your inbox.

Related in Oncology

From Other Specialties